Annual CAPEX
$28.30 M
+$11.80 M+71.52%
31 December 2023
Summary:
Neurocrine Biosciences annual capital expenditures is currently $28.30 million, with the most recent change of +$11.80 million (+71.52%) on 31 December 2023. During the last 3 years, it has risen by +$17.40 million (+159.63%). NBIX annual CAPEX is now -46.75% below its all-time high of $53.15 million, reached on 31 December 2004.NBIX CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CAPEX
$8.10 M
-$3.50 M-30.17%
30 September 2024
Summary:
Neurocrine Biosciences quarterly capital expenditures is currently $8.10 million, with the most recent change of -$3.50 million (-30.17%) on 30 September 2024. Over the past year, it has increased by +$500.00 thousand (+6.58%). NBIX quarterly CAPEX is now -66.32% below its all-time high of $24.05 million, reached on 31 March 2004.NBIX Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CAPEX
$36.30 M
+$500.00 K+1.40%
30 September 2024
Summary:
Neurocrine Biosciences TTM capital expenditures is currently $36.30 million, with the most recent change of +$500.00 thousand (+1.40%) on 30 September 2024. Over the past year, it has increased by +$11.60 million (+46.96%). NBIX TTM CAPEX is now -50.45% below its all-time high of $73.26 million, reached on 31 March 2004.NBIX TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +71.5% | +6.6% | +47.0% |
| 3 y3 years | +159.6% | +42.1% | +91.0% |
| 5 y5 years | +14.1% | +131.4% | +102.8% |
NBIX CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +159.6% | -30.2% | +576.5% | at high | +135.7% |
| 5 y | 5 years | at high | +159.6% | -30.2% | +576.5% | at high | +294.6% |
| alltime | all time | -46.8% | >+9999.0% | -66.3% | +576.5% | -50.5% | >+9999.0% |
Neurocrine Biosciences CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $8.10 M(-30.2%) | $36.30 M(+1.4%) |
| June 2024 | - | $11.60 M(+3.6%) | $35.80 M(+15.5%) |
| Mar 2024 | - | $11.20 M(+107.4%) | $31.00 M(+9.5%) |
| Dec 2023 | $28.30 M(+71.5%) | $5.40 M(-28.9%) | $28.30 M(+14.6%) |
| Sept 2023 | - | $7.60 M(+11.8%) | $24.70 M(+60.4%) |
| June 2023 | - | $6.80 M(-20.0%) | $15.40 M(-11.5%) |
| Mar 2023 | - | $8.50 M(+372.2%) | $17.40 M(+5.5%) |
| Dec 2022 | $16.50 M(-29.5%) | $1.80 M(-205.9%) | $16.50 M(-30.1%) |
| Sept 2022 | - | -$1.70 M(-119.3%) | $23.60 M(-23.9%) |
| June 2022 | - | $8.80 M(+15.8%) | $31.00 M(+17.0%) |
| Mar 2022 | - | $7.60 M(-14.6%) | $26.50 M(+13.2%) |
| Dec 2021 | $23.40 M(+114.7%) | $8.90 M(+56.1%) | $23.40 M(+23.2%) |
| Sept 2021 | - | $5.70 M(+32.6%) | $19.00 M(+38.7%) |
| June 2021 | - | $4.30 M(-4.4%) | $13.70 M(-2.8%) |
| Mar 2021 | - | $4.50 M(0.0%) | $14.10 M(+29.4%) |
| Dec 2020 | $10.90 M(-25.9%) | $4.50 M(+1025.0%) | $10.90 M(+18.5%) |
| Sept 2020 | - | $400.00 K(-91.5%) | $9.20 M(-25.2%) |
| June 2020 | - | $4.70 M(+261.5%) | $12.30 M(+1.7%) |
| Mar 2020 | - | $1.30 M(-53.6%) | $12.10 M(-17.7%) |
| Dec 2019 | $14.70 M(-40.7%) | $2.80 M(-20.0%) | $14.70 M(-17.9%) |
| Sept 2019 | - | $3.50 M(-22.2%) | $17.90 M(-33.1%) |
| June 2019 | - | $4.50 M(+15.4%) | $26.76 M(-0.5%) |
| Mar 2019 | - | $3.90 M(-35.0%) | $26.90 M(+8.5%) |
| Dec 2018 | $24.80 M(+257.3%) | $6.00 M(-51.5%) | $24.80 M(+17.1%) |
| Sept 2018 | - | $12.36 M(+166.2%) | $21.18 M(+82.2%) |
| June 2018 | - | $4.64 M(+157.9%) | $11.62 M(+57.5%) |
| Mar 2018 | - | $1.80 M(-24.3%) | $7.38 M(+6.3%) |
| Dec 2017 | $6.94 M(+68.9%) | $2.38 M(-15.2%) | $6.94 M(+41.3%) |
| Sept 2017 | - | $2.80 M(+606.3%) | $4.91 M(+70.3%) |
| June 2017 | - | $397.00 K(-70.9%) | $2.88 M(-39.0%) |
| Mar 2017 | - | $1.36 M(+292.5%) | $4.73 M(+15.1%) |
| Dec 2016 | $4.11 M(+112.4%) | $347.00 K(-55.3%) | $4.11 M(-10.5%) |
| Sept 2016 | - | $777.00 K(-65.4%) | $4.59 M(+11.2%) |
| June 2016 | - | $2.24 M(+202.7%) | $4.13 M(+72.4%) |
| Mar 2016 | - | $741.00 K(-10.5%) | $2.40 M(+23.8%) |
| Dec 2015 | $1.93 M(+20.0%) | $828.00 K(+162.0%) | $1.93 M(+25.2%) |
| Sept 2015 | - | $316.00 K(-38.0%) | $1.54 M(+3.1%) |
| June 2015 | - | $510.00 K(+82.1%) | $1.50 M(-8.5%) |
| Mar 2015 | - | $280.00 K(-36.2%) | $1.64 M(+1.6%) |
| Dec 2014 | $1.61 M(+195.8%) | $439.00 K(+63.2%) | $1.61 M(+18.2%) |
| Sept 2014 | - | $269.00 K(-58.6%) | $1.36 M(+21.1%) |
| June 2014 | - | $649.00 K(+154.5%) | $1.13 M(+52.0%) |
| Mar 2014 | - | $255.00 K(+33.5%) | $741.00 K(+36.0%) |
| Dec 2013 | $545.00 K(-43.9%) | $191.00 K(+516.1%) | $545.00 K(+37.6%) |
| Sept 2013 | - | $31.00 K(-88.3%) | $396.00 K(-41.1%) |
| June 2013 | - | $264.00 K(+347.5%) | $672.00 K(+7.3%) |
| Mar 2013 | - | $59.00 K(+40.5%) | $626.00 K(-35.5%) |
| Dec 2012 | $971.00 K(+29.5%) | $42.00 K(-86.3%) | $971.00 K(+0.2%) |
| Sept 2012 | - | $307.00 K(+40.8%) | $969.00 K(-20.8%) |
| June 2012 | - | $218.00 K(-46.0%) | $1.22 M(+7.9%) |
| Mar 2012 | - | $404.00 K(+910.0%) | $1.13 M(+51.2%) |
| Dec 2011 | $750.00 K(+138.1%) | $40.00 K(-92.9%) | $750.00 K(+3.9%) |
| Sept 2011 | - | $562.00 K(+339.1%) | $722.00 K(+193.5%) |
| June 2011 | - | $128.00 K(+540.0%) | $246.00 K(-26.6%) |
| Mar 2011 | - | $20.00 K(+66.7%) | $335.00 K(+6.3%) |
| Dec 2010 | $315.00 K | $12.00 K(-86.0%) | $315.00 K(+4.0%) |
| Sept 2010 | - | $86.00 K(-60.4%) | $303.00 K(+33.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $217.00 K(>+9900.0%) | $227.00 K(+548.6%) |
| Dec 2009 | $35.00 K(-97.4%) | $0.00(-100.0%) | $35.00 K(-79.7%) |
| Sept 2009 | - | $10.00 K(+900.0%) | $172.00 K(-10.4%) |
| June 2009 | - | $1000.00(-95.8%) | $192.00 K(-82.0%) |
| Mar 2009 | - | $24.00 K(-82.5%) | $1.06 M(-19.4%) |
| Dec 2008 | $1.32 M(+111.9%) | $137.00 K(+356.7%) | $1.32 M(+0.3%) |
| Sept 2008 | - | $30.00 K(-96.6%) | $1.32 M(-17.9%) |
| June 2008 | - | $874.00 K(+211.0%) | $1.61 M(+91.2%) |
| Mar 2008 | - | $281.00 K(+111.3%) | $840.00 K(+34.6%) |
| Dec 2007 | $624.00 K(-79.9%) | $133.00 K(-58.2%) | $624.00 K(+8.1%) |
| Sept 2007 | - | $318.00 K(+194.4%) | $577.00 K(+6.7%) |
| June 2007 | - | $108.00 K(+66.2%) | $541.00 K(-77.9%) |
| Mar 2007 | - | $65.00 K(-24.4%) | $2.45 M(-21.1%) |
| Dec 2006 | $3.11 M(-57.0%) | $86.00 K(-69.5%) | $3.11 M(-48.1%) |
| Sept 2006 | - | $282.00 K(-86.0%) | $6.00 M(-18.8%) |
| June 2006 | - | $2.02 M(+179.8%) | $7.38 M(+14.6%) |
| Mar 2006 | - | $722.00 K(-75.7%) | $6.44 M(-10.9%) |
| Dec 2005 | $7.24 M(-86.4%) | $2.97 M(+78.0%) | $7.24 M(-26.6%) |
| Sept 2005 | - | $1.67 M(+54.9%) | $9.86 M(-35.6%) |
| June 2005 | - | $1.08 M(-28.8%) | $15.31 M(-50.0%) |
| Mar 2005 | - | $1.51 M(-72.9%) | $30.61 M(-42.4%) |
| Dec 2004 | $53.15 M(+5.4%) | $5.59 M(-21.4%) | $53.15 M(-18.2%) |
| Sept 2004 | - | $7.12 M(-56.5%) | $64.99 M(-5.5%) |
| June 2004 | - | $16.38 M(-31.9%) | $68.77 M(-6.1%) |
| Mar 2004 | - | $24.05 M(+37.9%) | $73.26 M(+45.2%) |
| Dec 2003 | $50.44 M(+851.7%) | $17.44 M(+60.0%) | $50.44 M(+47.0%) |
| Sept 2003 | - | $10.90 M(-47.8%) | $34.31 M(+37.6%) |
| June 2003 | - | $20.87 M(+1591.2%) | $24.93 M(+306.0%) |
| Mar 2003 | - | $1.23 M(-5.5%) | $6.14 M(+15.9%) |
| Dec 2002 | $5.30 M(+39.3%) | $1.31 M(-14.4%) | $5.30 M(+22.1%) |
| Sept 2002 | - | $1.52 M(-26.6%) | $4.34 M(+6.8%) |
| June 2002 | - | $2.08 M(+429.8%) | $4.06 M(+23.1%) |
| Mar 2002 | - | $392.00 K(+13.3%) | $3.30 M(-13.3%) |
| Dec 2001 | $3.81 M(+55.9%) | $346.00 K(-72.3%) | $3.81 M(-9.6%) |
| Sept 2001 | - | $1.25 M(-5.1%) | $4.21 M(+25.4%) |
| June 2001 | - | $1.31 M(+46.3%) | $3.36 M(+20.4%) |
| Mar 2001 | - | $898.00 K(+19.4%) | $2.79 M(+14.3%) |
| Dec 2000 | $2.44 M(+16.2%) | $752.00 K(+90.9%) | $2.44 M(+36.5%) |
| Sept 2000 | - | $394.00 K(-47.2%) | $1.79 M(-22.1%) |
| June 2000 | - | $746.00 K(+36.1%) | $2.29 M(+12.0%) |
| Mar 2000 | - | $548.00 K(+448.0%) | $2.05 M(-2.5%) |
| Dec 1999 | $2.10 M(-43.2%) | $100.00 K(-88.9%) | $2.10 M(-19.2%) |
| Sept 1999 | - | $900.00 K(+80.0%) | $2.60 M(-16.1%) |
| June 1999 | - | $500.00 K(-16.7%) | $3.10 M(-20.5%) |
| Mar 1999 | - | $600.00 K(0.0%) | $3.90 M(+5.4%) |
| Dec 1998 | $3.70 M(-42.2%) | $600.00 K(-57.1%) | $3.70 M(-47.1%) |
| Sept 1998 | - | $1.40 M(+7.7%) | $7.00 M(+22.8%) |
| June 1998 | - | $1.30 M(+225.0%) | $5.70 M(-10.9%) |
| Mar 1998 | - | $400.00 K(-89.7%) | $6.40 M(0.0%) |
| Dec 1997 | $6.40 M(+178.3%) | $3.90 M(+3800.0%) | $6.40 M(+113.3%) |
| Sept 1997 | - | $100.00 K(-95.0%) | $3.00 M(-25.0%) |
| June 1997 | - | $2.00 M(+400.0%) | $4.00 M(+66.7%) |
| Mar 1997 | - | $400.00 K(-20.0%) | $2.40 M(+4.3%) |
| Dec 1996 | $2.30 M | $500.00 K(-54.5%) | $2.30 M(+27.8%) |
| Sept 1996 | - | $1.10 M(+175.0%) | $1.80 M(+157.1%) |
| June 1996 | - | $400.00 K(+33.3%) | $700.00 K(+133.3%) |
| Mar 1996 | - | $300.00 K | $300.00 K |
FAQ
- What is Neurocrine Biosciences annual capital expenditures?
- What is the all time high annual CAPEX for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual CAPEX year-on-year change?
- What is Neurocrine Biosciences quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly CAPEX year-on-year change?
- What is Neurocrine Biosciences TTM capital expenditures?
- What is the all time high TTM CAPEX for Neurocrine Biosciences?
- What is Neurocrine Biosciences TTM CAPEX year-on-year change?
What is Neurocrine Biosciences annual capital expenditures?
The current annual CAPEX of NBIX is $28.30 M
What is the all time high annual CAPEX for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual capital expenditures is $53.15 M
What is Neurocrine Biosciences annual CAPEX year-on-year change?
Over the past year, NBIX annual capital expenditures has changed by +$11.80 M (+71.52%)
What is Neurocrine Biosciences quarterly capital expenditures?
The current quarterly CAPEX of NBIX is $8.10 M
What is the all time high quarterly CAPEX for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly capital expenditures is $24.05 M
What is Neurocrine Biosciences quarterly CAPEX year-on-year change?
Over the past year, NBIX quarterly capital expenditures has changed by +$500.00 K (+6.58%)
What is Neurocrine Biosciences TTM capital expenditures?
The current TTM CAPEX of NBIX is $36.30 M
What is the all time high TTM CAPEX for Neurocrine Biosciences?
Neurocrine Biosciences all-time high TTM capital expenditures is $73.26 M
What is Neurocrine Biosciences TTM CAPEX year-on-year change?
Over the past year, NBIX TTM capital expenditures has changed by +$11.60 M (+46.96%)